Add BrightSurf on Google Email

Science News for April 15, 2012


Hebrew SeniorLife researchers discover genes linked to osteoporosis, bone breaks

Hebrew SeniorLife researchers have identified 56 genetic variants associated with osteoporosis and bone mineral density. The study found that these variants can increase the risk of bone fractures, with women over 65 facing a higher risk. The findings may lead to personalized gene-based treatments for osteoporosis.

Latest research confirms genetic susceptibility to lung cancer

A recent study published in the Journal of Thoracic Oncology reveals that Japanese patients with lung cancer are more likely to harbor specific genetic mutations and have a different risk profile compared to Western patients. The research highlights the importance of considering genetic factors in lung cancer diagnosis and treatment.

SourceInternational Association for the Study of Lung Cancer·JournalJournal of Thoracic Oncology·DateApr 15, 2012

Salk scientists discover how plants grow to escape shade

Researchers found that phytochrome interacting factor 7 (PIF7) serves as key messenger between plant's cellular light sensors and production of auxins, hormones that stimulate stem growth. This discovery could lead to high-yield crops that gather light more efficiently and make better use of farmland.

SourceSalk Institute·JournalGenes & Development·DateApr 15, 2012

An Achilles heel of AML

Researchers have discovered that activating mutations in the FLT3 gene play a crucial role in acute myeloid leukemia, making it an attractive target for new treatments. The study identifies drug-resistant mutations in FLT3 and suggests that therapies involving combinations of multiple drugs could suppress these mutated forms.

Urgent research needed to determine most effective follow-up care for lung cancer patients

Researchers analyzed four studies and found that regular follow-up reduces crisis-driven health episodes. While no preferred method was determined, the authors recommend guidelines for initial specialist appointments and protocol-driven follow-up led by a lung cancer clinical nurse specialist.

SourceInternational Association for the Study of Lung Cancer·JournalJournal of Thoracic Oncology·DateApr 15, 2012